Myeloid Therapeutics’ releases data on the first mRNA gene editing tool: CRISPR-Enabled Autonomous Transposable Element (CREATE), an RNA-based genome editing system that offers a programmable, versatile, and cost-effective approach to large-scale gene delivery and genome editing not been seen before.
We're thrilled to share the next generation of gene editing: Myeloid Therapeutics’ CRISPR-Enabled Autonomous Transposable Element (CREATE), an RNA-based genome editing system that offers a programmable, versatile, and cost-effective approach to large-scale gene delivery and genome editing not been seen before. We're incredibly proud of our team's dedication and ingenuity in helping to create a paradigm shift in gene editing for the benefit of patients worldwide! Read the full manuscript here: https://bit.ly/3SFXRv8 #MyeloidTherapeutics #CREATE #GeneEditing #mRNA #Biotech #Innovation